Sangamo Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.42 | -$0.08 | -$0.21 |
| Q2 2024 | 2 | -$0.29 | -$0.05 | -$0.15 |
| Q3 2024 | 3 | -$0.03 | -$0.01 | -$0.02 |
| Q4 2024 | 5 | -$0.36 | $0.21 | -$0.09 |
| Q1 2025 | 2 | $0.07 | $0.39 | $0.20 |
| Q2 2025 | 1 | -$0.19 | -$0.03 | -$0.10 |
| Q3 2025 | 1 | -$0.19 | -$0.04 | -$0.10 |
| Q4 2025 | 1 | -$0.14 | -$0.03 | -$0.07 |
| Q1 2026 | 1 | -$0.16 | -$0.03 | -$0.08 |
| Q2 2026 | 1 | -$0.15 | -$0.03 | -$0.08 |
| Q3 2026 | 1 | -$0.14 | -$0.03 | -$0.07 |
| Q4 2026 | 1 | -$0.13 | -$0.02 | -$0.06 |
Sangamo Therapeutics, Inc. Earnings Date And Information
Sangamo Therapeutics, Inc. last posted its earnings results on Tuesday, August 6th, 2024. The company reported $-0.17 earnings per share for the quarter, missing analysts' consensus estimates of $-0.16 by $0.01. The company had revenue of 49.41 M for the quarter and had revenue of 176.23 M for the year. Sangamo Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.48 diluted earnings per share) and currently has a price-to-earnings ratio of -2.9. Sangamo Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 19th, 2025 based on prior year's report dates.
Sangamo Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/12/2024 | Q3 2024 | $0.05 | $20.92 M | $49.41 M | ||
| 08/06/2024 | Q2 2024 | -$0.16 | -$0.18 | -0.02 | $6.88 M | $356,000 |
| 05/09/2024 | Q1 2024 | -$0.22 | -$0.27 | -0.05 | $481,000 | |
| 03/13/2024 | Q4 2023 | -$0.25 | -$0.34 | -0.09 | $2.04 M | |
| 11/01/2023 | Q3 2023 | -$0.33 | -$0.59 | -0.26 | $9.36 M | $9.40 M |
| 08/08/2023 | Q2 2023 | -$0.35 | -$0.66 | -0.31 | $16.75 M | $6.84 M |
| 05/08/2023 | Q1 2023 | -$0.33 | $0.13 | 0.46 | $157.96 M | |
| 02/22/2023 | Q4 2022 | -$0.32 | $27.23 M | |||
| 11/03/2022 | Q3 2022 | -$0.35 | -$0.34 | 0.01 | $26.59 M | $26.46 M |
| 08/04/2022 | Q2 2022 | -$0.35 | -$0.29 | 0.06 | $24.63 M | $29.38 M |
| 05/05/2022 | Q1 2022 | -$0.32 | -$0.30 | 0.02 | $28.23 M | |
| 02/24/2022 | Q4 2021 | -$0.34 | -$0.26 | 0.08 | $27.99 M | |
| 11/04/2021 | Q3 2021 | -$0.34 | -$0.33 | 0.01 | $25.96 M | $28.56 M |
| 08/05/2021 | Q2 2021 | -$0.30 | -$0.33 | -0.03 | $26.53 M | $27.87 M |
| 05/04/2021 | Q1 2021 | -$0.29 | -$0.32 | -0.03 | $26.28 M | |
| 02/24/2021 | Q4 2020 | -$0.18 | -$0.29 | -0.11 | $25.80 M | |
| 11/04/2020 | Q3 2020 | -$0.24 | -$0.01 | 0.23 | $26.55 M | $57.76 M |
| 08/05/2020 | Q2 2020 | $0.41 | -$0.26 | -0.67 | $102.71 M | $21.55 M |
| 05/11/2020 | Q1 2020 | -$0.23 | -$0.37 | -0.14 | $13.08 M | |
| 02/28/2020 | Q4 2019 | -$0.31 | $0.04 | 0.35 | $54.85 M |
Sangamo Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Sangamo Therapeutics, Inc.'s earnings date?
Sangamo Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 19th, 2025 based off last year's report dates.
-
How can I listen to Sangamo Therapeutics, Inc.'s earnings conference call?
The conference call for Sangamo Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Sangamo Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Sangamo Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Sangamo Therapeutics, Inc. generate each year?
Sangamo Therapeutics, Inc. (:SGMO) has a recorded annual revenue of $176.23 M.
-
How much profit does Sangamo Therapeutics, Inc. generate each year?
Sangamo Therapeutics, Inc. (:SGMO) has a recorded net income of $176.23 M. Sangamo Therapeutics, Inc. has generated $-1.48 earnings per share over the last four quarters.
-
What is Sangamo Therapeutics, Inc.'s price-to-earnings ratio?
Sangamo Therapeutics, Inc. (:SGMO) has a price-to-earnings ratio of -2.9 and price/earnings-to-growth ratio is -0.06.
